| 000 | 01563 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513042530.0 | ||
| 264 | 0 | _c19950622 | |
| 008 | 199506s 0 0 eng d | ||
| 022 | _a0300-8916 | ||
| 024 | 7 |
_a10.1177/030089169508100110 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDi Lauro, L | |
| 245 | 0 | 0 |
_aSequential subcutaneous thymopentin, interferon alpha-2a and interleukin-2 in metastatic renal cell cancer. _h[electronic resource] |
| 260 |
_bTumori _c |
||
| 300 |
_a42-4 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xtherapy |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 |
_aKidney Neoplasms _xtherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aThymopentin _xadministration & dosage |
| 700 | 1 | _aDel Medico, P | |
| 700 | 1 | _aCarpano, S | |
| 700 | 1 | _aCancrini, A | |
| 700 | 1 | _aGionfra, T | |
| 700 | 1 | _aVici, P | |
| 700 | 1 | _aRosselli, M | |
| 700 | 1 | _aLopez, M | |
| 773 | 0 |
_tTumori _gvol. 81 _gno. 1 _gp. 42-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/030089169508100110 _zAvailable from publisher's website |
| 999 |
_c7753907 _d7753907 |
||